Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 10.334
Filtrer
2.
Biol Lett ; 20(6): 20230601, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38863347

RÉSUMÉ

Glycation reactions play a key role in the senescence process and are involved in numerous age-related pathologies, such as diabetes complications or Alzheimer's disease. As a result, past studies on glycation have mostly focused on human and laboratory animal models for medical purposes. Very little is known about glycation and its link to senescence in wild animal species. Yet, despite feeding on high-sugar diets, several bat and bird species are long-lived and seem to escape the toxic effects of high glycaemia. The study of these models could open new avenues both for understanding the mechanisms that coevolved with glycation resistance and for treating the damaging effects of glycations in humans. Our understanding of glycaemia's correlation to proxies of animals' pace of life is emerging in few wild species; however, virtually nothing is known about their resistance to glycation, nor on the relationship between glycation, species' life-history traits and individual fitness. Our review summarizes the scarce current knowledge on the links between glycation and life-history traits in non-conventional animal models, highlighting the predominance of avian research. We also investigate some key molecular and physiological parameters involved in glycation regulation, which hold promise for future research on fitness and senescence of individuals.


Sujet(s)
Caractéristiques du cycle biologique , Animaux , Oiseaux/physiologie , Modèles animaux , Glycosylation , Vieillissement , Produits terminaux de glycation avancée/métabolisme
3.
Int J Biol Macromol ; 272(Pt 1): 132859, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38838889

RÉSUMÉ

Methylglyoxal (MGO), a highly reactive precursor of advanced glycation end products, is endogenously produced and prevalent in various food products. This study aimed to characterize protein modifications in SH-SY5Y human neuroblastoma cells induced by MGO and identify potential biomarkers for its exposure and toxicity. A shot-gun proteomic analysis was applied to characterize protein modifications in cells incubated with and without exogenous MGO. Seventy-seven proteins were identified as highly susceptible to MGO modification, among which eight, including vimentin and histone H2B type 2-F, showing concentration-dependent modifications by externally added MGO, were defined as biomarkers for exogenous MGO exposure. Remarkably, up to 10 modification sites were identified on vimentin. Myosin light polypeptide 6 emerged as a biomarker for MGO toxicity, with modifications exclusively observed under cytotoxic MGO levels. Additionally, proteins like serine/threonine-protein kinase SIK2 and calcyphosin, exhibiting comparable or even higher modification levels in control compared to exogenous MGO-treated cells, were defined as biomarkers for endogenous exposure. Bioinformatics analysis revealed that motor proteins, cytoskeleton components, and glycolysis proteins were overrepresented among those highly susceptible to MGO modification. These results identify biomarkers for both endogenous and exogenous MGO exposure and provide insights into the cellular effects of endogenously formed versus externally added MGO.


Sujet(s)
Neuroblastome , Protéomique , Méthylglyoxal , Humains , Méthylglyoxal/métabolisme , Méthylglyoxal/pharmacologie , Méthylglyoxal/toxicité , Protéomique/méthodes , Neuroblastome/métabolisme , Neuroblastome/anatomopathologie , Lignée cellulaire tumorale , Produits terminaux de glycation avancée/métabolisme , Marqueurs biologiques/métabolisme , Protéome/métabolisme
4.
Int J Mol Sci ; 25(11)2024 May 21.
Article de Anglais | MEDLINE | ID: mdl-38891783

RÉSUMÉ

Skin yellowness is a hallmark of dull or unhealthy skin, particularly among Asians. Previous research has indicated a link between skin glycation and skin yellowness. However, the specific glycated chemicals contributing to yellowish skin appearance have not been identified yet. Using HPLC-PDA-HRMS coupled with native and artificially glycated human epidermal explant skin, we identified intensely yellow colored glycated chromophores "(1R, 8aR) and (1S, 8aR)-4-(2-furyl)-7-[(2-furyl)-methylidene]-2-hydroxy-2H,7H,8AH-pyrano-[2,3-B]-pyran-3-one" (abbreviated as AGEY) from human skin samples for the first time. The abundance of AGEY was strongly correlated with skin yellowness in the multiple skin explant tissues. We further confirmed the presence of AGEY in cultured human keratinocytes and 3D reconstructed human epidermal (RHE) models. Additionally, we demonstrated that a combination of four cosmetic compounds with anti-glycation properties can inhibit the formation of AGEY and reduce yellowness in the RHE models. In conclusion, we have identified specific advanced glycation end products with an intense yellow color, namely AGEY, in human skin tissues for the first time. The series of study results highlighted the significant contribution of AGEY to the yellow appearance of the skin. Furthermore, we have identified a potential cosmetic solution to mitigate AGEY formation, leading to a reduction in yellowness in the in vitro RHE models.


Sujet(s)
Produits terminaux de glycation avancée , Kératinocytes , Peau , Humains , Produits terminaux de glycation avancée/métabolisme , Peau/métabolisme , Kératinocytes/métabolisme , Kératinocytes/effets des médicaments et des substances chimiques , Chromatographie en phase liquide à haute performance , Glycosylation , Épiderme/métabolisme , Cosmétiques/composition chimique , Femelle , Adulte , Pigmentation de la peau/effets des médicaments et des substances chimiques
5.
Int J Mol Sci ; 25(11)2024 May 29.
Article de Anglais | MEDLINE | ID: mdl-38892134

RÉSUMÉ

Type 2 diabetes mellitus (T2DM) is a risk factor for male infertility, but the underlying molecular mechanisms remain unclear. Advanced glycation end products (AGEs) are pathogenic molecules for diabetic vascular complications. Here, we investigated the effects of the DNA aptamer raised against AGEs (AGE-Apt) on testicular and sperm abnormalities in a T2DM mouse model. KK-Ay (DM) and wild-type (non-DM) 4- and 7-week-old male mice were sacrificed to collect the testes and spermatozoa for immunofluorescence, RT-PCR, and histological analyses. DM and non-DM 7-week-old mice were subcutaneously infused with the AGE-Apt or control-aptamer for 6 weeks and were then sacrificed. Plasma glucose, testicular AGEs, and Rage gene expression in 4-week-old DM mice and plasma glucose, testicular AGEs, oxidative stress, and pro-inflammatory gene expressions in 7-week-old DM mice were higher than those in age-matched non-DM mice, the latter of which was associated with seminiferous tubular dilation. AGE-Apt did not affect glycemic parameters, but it inhibited seminiferous tubular dilation, reduced the number of testicular macrophages and apoptotic cells, and restored the decrease in sperm concentration, motility, and viability of 13-week-old DM mice. Our findings suggest that AGEs-Apt may improve sperm abnormality by suppressing AGE-RAGE-induced oxidative stress and inflammation in the testes of DM mice.


Sujet(s)
Aptamères nucléotidiques , Diabète expérimental , Diabète de type 2 , Produits terminaux de glycation avancée , Inflammation , Stress oxydatif , Récepteur spécifique des produits finaux de glycosylation avancée , Mobilité des spermatozoïdes , Testicule , Animaux , Mâle , Stress oxydatif/effets des médicaments et des substances chimiques , Produits terminaux de glycation avancée/métabolisme , Souris , Aptamères nucléotidiques/pharmacologie , Testicule/métabolisme , Testicule/effets des médicaments et des substances chimiques , Testicule/anatomopathologie , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Diabète expérimental/métabolisme , Mobilité des spermatozoïdes/effets des médicaments et des substances chimiques , Diabète de type 2/métabolisme , Diabète de type 2/anatomopathologie , Inflammation/métabolisme , Inflammation/anatomopathologie , Spermatozoïdes/métabolisme , Spermatozoïdes/effets des médicaments et des substances chimiques , Numération des spermatozoïdes
6.
J Mater Chem B ; 12(25): 6155-6163, 2024 Jun 27.
Article de Anglais | MEDLINE | ID: mdl-38842019

RÉSUMÉ

Advanced glycation end products (AGEs) play a pivotal role in the aging process, regarded as a hallmark of aging. Despite their significance, the absence of adequate monitoring tools has hindered the exploration of the relationship between AGEs and aging. Here, we present a novel AGE-selective probe, AGO, for the first time. AGO exhibited superior sensitivity in detecting AGEs compared to the conventional method of measuring autofluorescence from AGEs. Furthermore, we validated AGO's ability to detect AGEs based on kinetics, demonstrating a preference for ribose-derived AGEs. Lastly, AGO effectively visualized glycation products in a collagen-based mimicking model of glycation. We anticipate that this study will enhance the molecular tool sets available for comprehending the physiological processes of AGEs during aging.


Sujet(s)
Colorants fluorescents , Produits terminaux de glycation avancée , Produits terminaux de glycation avancée/analyse , Produits terminaux de glycation avancée/métabolisme , Colorants fluorescents/composition chimique , Colorants fluorescents/synthèse chimique , Humains , Collagène/composition chimique , Collagène/métabolisme , Structure moléculaire , Imagerie optique
7.
Nutrients ; 16(12)2024 Jun 11.
Article de Anglais | MEDLINE | ID: mdl-38931185

RÉSUMÉ

Advanced glycation end products (AGEs) have been implicated in chronic diseases in adults, but their role in paediatric populations remains uncertain. This study, conducted on the Italian sample of the I.Family project, aimed to investigate the relationship between dietary and urinary fluorescent AGEs in children and adolescents. The secondary objective was to investigate the sources of dietary AGEs (dAGEs) and their association with dietary composition and anthropometric parameters. Dietary data were collected from 1048 participants via 24 h dietary recall in 2013/2014 to estimate dAGEs intake, while urinary fluorescent AGE levels were measured in 544 individuals. Participants were stratified based on dAGEs intake and compared with respect to urinary fluorescent AGE levels, anthropometric measurements, and dietary intake. The results showed no significant correlation between dietary and urinary fluorescent AGE levels, nor between dAGEs and anthropometric parameters. Notably, higher dAGEs were associated with a diet richer in protein (especially from meat sources) and fat and lower in carbohydrates. In addition, the consumption of ultra-processed foods was lower in participants with a higher DAGE intake. This study highlights the lack of a clear association between dietary and urinary fluorescent AGEs in children, but suggests a distinctive dietary pattern associated with increased dAGEs intake. Further investigation is warranted to elucidate the potential health implications of dAGEs in paediatric populations.


Sujet(s)
Régime alimentaire , Produits terminaux de glycation avancée , Humains , Enfant , Produits terminaux de glycation avancée/urine , Mâle , Femelle , Adolescent , Italie , Études transversales , Anthropométrie , Produits terminaux de glycation avancée alimentaires
8.
Nutrients ; 16(12)2024 Jun 16.
Article de Anglais | MEDLINE | ID: mdl-38931253

RÉSUMÉ

Advanced glycation end products (AGEs) accumulate in the plasma of pregnant women with hyperglycemia, potentially inducing oxidative stress and fetal developmental abnormalities. Although intrauterine hyperglycemia has been implicated in excessive fetal growth, the effects of maternal AGEs on fetal development remain unclear. We evaluated the differentiation regulators and cellular signaling in the skeletal muscles of infants born to control mothers (ICM), diabetic mothers (IDM), and diabetic mothers supplemented with either cis-palmitoleic acid (CPA) or trans-palmitoleic acid (TPA). Cell viability, reactive oxygen species levels, and myotube formation were assessed in AGE-exposed C2C12 cells to explore potential mitigation by CPA and TPA. Elevated receptors for AGE expression and decreased Akt and AMPK phosphorylation were evident in rat skeletal muscles in IDM. Maternal palmitoleic acid supplementation alleviated insulin resistance by downregulating RAGE expression and enhancing Akt phosphorylation. The exposure of the C2C12 cells to AGEs reduced cell viability and myotube formation and elevated reactive oxygen species levels, which were attenuated by CPA or TPA supplementation. This suggests that maternal hyperglycemia and plasma AGEs may contribute to skeletal muscle disorders in offspring, which are mitigated by palmitoleic acid supplementation. Hence, the maternal intake of palmitoleic acid during pregnancy may have implications for fetal health.


Sujet(s)
Acides gras monoinsaturés , Produits terminaux de glycation avancée , Muscles squelettiques , Espèces réactives de l'oxygène , Récepteur spécifique des produits finaux de glycosylation avancée , Acides gras monoinsaturés/pharmacologie , Produits terminaux de glycation avancée/métabolisme , Femelle , Animaux , Grossesse , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Rats , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Espèces réactives de l'oxygène/métabolisme , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Souris , Compléments alimentaires , Protéines proto-oncogènes c-akt/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Insulinorésistance , Humains , Phosphorylation , Rat Sprague-Dawley , Grossesse chez les diabétiques/métabolisme , Grossesse chez les diabétiques/traitement médicamenteux , Mâle , Développement foetal/effets des médicaments et des substances chimiques
9.
Nutrients ; 16(12)2024 Jun 19.
Article de Anglais | MEDLINE | ID: mdl-38931293

RÉSUMÉ

Skin autofluorescence (sAF) measurement is a non-invasive method used to assess tissue advanced glycation end product (AGE) accumulation. This study aims to characterize sAF's association with (1) glycated hemoglobin (HbA1c) values, (2) cardiovascular risk markers, and (3) common comorbidities (autoimmune thyroiditis, celiac disease) in children with type 1 diabetes (T1D). MATERIALS AND METHODS: A total of 348 children with T1D aged 3-18 years and 85 age- and gender-matched control subjects were enrolled. sAF was quantified using an AGE Reader (Diagnoptics BV, The Netherlands). The analysis covered HbA1c, blood lipid, and C-reactive protein (CRP) levels, ambulatory blood pressure monitoring records, and body composition parameters. The associations between variables and sAF were assessed using the Mann-Whitney U test and Spearman correlation. RESULTS: We observed significantly higher sAF values in the T1D group compared to the control (1.40 [1.27-1.53] vs. 1.20 [1.07-1.30, AU]; p = 0.004), consistent across all tested age groups. In the T1D group, sAF was positively correlated with current HbA1c, mean of historical HbA1c values, and T1D duration (r values, respectively: 0.27, 0.22, 0.14, all p < 0.01). Percentage of body fat was positively correlated with sAF (r = 0.120; p = 0.044). No significant correlations were found between sAF and lipid fractions, Z-score of BMI, parameters from 24 h ambulatory blood pressure monitoring, or the amount of albumin excreted in urine. sAF was positively correlated with CRP (r = 0.17, p < 0.05). sAF was significantly higher in patients with concomitant celiac disease (1.53 [1.43-1.63] vs. 1.40 [1.27-1.53, AU], p = 0.001). CONCLUSION: Among young T1D patients with relatively brief diabetes duration, sAF effectively mirrors prior glycemic control, as presented by historical average HbA1c. However, associations with conventional CV risk markers are not evident. The higher sAF values in patients with celiac disease warrant further exploration.


Sujet(s)
Diabète de type 1 , Hémoglobine glyquée , Produits terminaux de glycation avancée , Facteurs de risque de maladie cardiaque , Peau , Humains , Enfant , Hémoglobine glyquée/analyse , Hémoglobine glyquée/métabolisme , Diabète de type 1/complications , Diabète de type 1/sang , Femelle , Mâle , Adolescent , Peau/métabolisme , Enfant d'âge préscolaire , Marqueurs biologiques/sang , Maladies cardiovasculaires/étiologie , Maladies cardiovasculaires/épidémiologie , Maladie chronique , Imagerie optique , Protéine C-réactive/analyse , Protéine C-réactive/métabolisme , Études cas-témoins , Maladie coeliaque/complications , Maladie coeliaque/sang , Comorbidité
10.
J Nutr Sci Vitaminol (Tokyo) ; 70(3): 252-261, 2024.
Article de Anglais | MEDLINE | ID: mdl-38945891

RÉSUMÉ

Pyridoxamine (PM) is one of the natural vitamins B6 (VB6) and functions as an endogenous inhibitor for the formation of AGEs (advanced glycation end products). The AGEs are implicated in aging, diabetes, and various neuropsychiatric disease, including schizophrenia, Alzheimer's disease, and Parkinson's disease. However, it is unclear whether the absence of PM per se accumulates AGEs in vivo and causes behavioral dysfunctions. To address these points, we raised PM-deficient fruit flies, Drosophila melanogaster, with the sterilized defined medium. Flies reared in a PM-deficient medium accumulated AGEs and reduced lifespan, impaired gustatory response, sleep, courtship behavior, and olfactory learning. These results suggest that PM suppresses AGE accumulation in vivo and is required for regulating innate and empirical behaviors.


Sujet(s)
Comportement animal , Drosophila melanogaster , Produits terminaux de glycation avancée , Longévité , Pyridoxamine , Animaux , Produits terminaux de glycation avancée/métabolisme , Pyridoxamine/pharmacologie , Mâle , Sommeil/physiologie , Femelle , Comportement sexuel chez les animaux/physiologie , Comportement sexuel chez les animaux/effets des médicaments et des substances chimiques , Apprentissage
11.
Nutrients ; 16(11)2024 May 23.
Article de Anglais | MEDLINE | ID: mdl-38892513

RÉSUMÉ

BACKGROUND: Biochemical events provoked by oxidative stress and advanced glycation may be inhibited by combining natural bioactives with classic therapeutic agents, which arise as strategies to mitigate diabetic complications. The aim of this study was to investigate whether lycopene combined with a reduced insulin dose is able to control glycemia and to oppose glycoxidative stress in kidneys of diabetic rats. METHODS: Streptozotocin-induced diabetic rats were treated with 45 mg/kg lycopene + 1 U/day insulin for 30 days. The study assessed glycemia, insulin sensitivity, lipid profile and paraoxonase 1 (PON-1) activity in plasma. Superoxide dismutase (SOD) and catalase (CAT) activities and the protein levels of advanced glycation end-product receptor 1 (AGE-R1) and glyoxalase-1 (GLO-1) in the kidneys were also investigated. RESULTS: An effective glycemic control was achieved with lycopene plus insulin, which may be attributed to improvements in insulin sensitivity. The combined therapy decreased the dyslipidemia and increased the PON-1 activity. In the kidneys, lycopene plus insulin increased the activities of SOD and CAT and the levels of AGE-R1 and GLO-1, which may be contributing to the antialbuminuric effect. CONCLUSIONS: These findings demonstrate that lycopene may aggregate favorable effects to insulin against diabetic complications resulting from glycoxidative stress.


Sujet(s)
Antioxydants , Diabète expérimental , Produits terminaux de glycation avancée , Insuline , Rein , Lycopène , Stress oxydatif , Rat Wistar , Animaux , Lycopène/pharmacologie , Rein/effets des médicaments et des substances chimiques , Rein/métabolisme , Diabète expérimental/traitement médicamenteux , Diabète expérimental/métabolisme , Produits terminaux de glycation avancée/métabolisme , Antioxydants/pharmacologie , Mâle , Insuline/sang , Insuline/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Rats , Glycémie/métabolisme , Glycémie/effets des médicaments et des substances chimiques , Superoxide dismutase/métabolisme , Catalase/métabolisme , Aryldialkylphosphatase/métabolisme , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Insulinorésistance , Lactoyl glutathione lyase/métabolisme , Association de médicaments , Hypoglycémiants/pharmacologie , Néphropathies diabétiques/traitement médicamenteux , Néphropathies diabétiques/métabolisme
12.
Nutr Diabetes ; 14(1): 37, 2024 Jun 01.
Article de Anglais | MEDLINE | ID: mdl-38824123

RÉSUMÉ

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic medical condition affecting more than 95% of people with diabetes. Traditionally, some medicinal plants have been considered as an effective approach in management of T2DM. This trial evaluated the effects of date seed powder (DSP) on glycemia indices and oxidative stress in T2DM patients. METHODS: In this trail, 43 patients with T2DM were randomized to two groups: either 5 g/d of the DSP or placebo for 8 weeks. Levels of glycemic indices, lipolpolysaccharide (LPS), and soluble receptor for advanced glycation end products (s-RAGE), as well as other parameters associated with oxidative stress were assessed at baseline and after 8 weeks. Independent t-test and analysis of covariance (ANCOVA) were used for between-groups comparisons at baseline and the post-intervention phase, respectively. RESULTS: The results showed that supplementation with DSP significantly decreased HbA1c (-0.30 ± 0.48%), insulin (-1.70 ± 2.21 µU/ml), HOMA-IR (-1.05 ± 0.21), HOMA-B (-0.76 ± 21.21), lipopolysaccharide (LPS) (-3.68 ± 6.05 EU/mL), and pentosidine (118.99 ± 21.67 pg/mL) (P < 0.05, ANCOVA adjusted for baseline and confounding factors). On the other hand, DSP supplementation significantly increased total antioxidant capacity (TAC) (0.50 ± 0.26 mmol/L), superoxide dismutase (SOD) (0.69 ± 0.32 U/ml), and s-RAGE (240.13 ± 54.25 pg/mL) compared to the placebo group. FPG, hs-CRP, GPx, CML, and uric acid had no significant within- or between-group changes. CONCLUSION: Supplementation of DSP could be considered an effective strategy to improve glycemic control and oxidative stress in T2DM patients (Registration ID at www.irct.ir : IRCT20150205020965N10).


Sujet(s)
Glycémie , Diabète de type 2 , Hémoglobine glyquée , Produits terminaux de glycation avancée , Stress oxydatif , Graines , Humains , Diabète de type 2/sang , Diabète de type 2/traitement médicamenteux , Mâle , Femelle , Adulte d'âge moyen , Produits terminaux de glycation avancée/sang , Stress oxydatif/effets des médicaments et des substances chimiques , Hémoglobine glyquée/analyse , Glycémie/effets des médicaments et des substances chimiques , Récepteur spécifique des produits finaux de glycosylation avancée/sang , Insuline/sang , Adulte , Indice glycémique/effets des médicaments et des substances chimiques , Sujet âgé
13.
Food Res Int ; 189: 114552, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38876591

RÉSUMÉ

The objective of this study was to assess the effects of simulated digestion on the formation of α-dicarbonyl compounds (α-DCs) in chocolates. For that purpose, the concentrations of glyoxal and methylglyoxal in chocolates were determined through High-Performance Liquid Chromatography (HPLC) analysis before and after in vitro digestion. The initial concentrations ranged from 0.0 and 228.2 µg/100 g, and 0.0 and 555.1 for glyoxal and methylglyoxal, respectively. Following digestion, there was a significant increase in both glyoxal and methylglyoxal levels, reaching up to 1804 % and 859 %, respectively. The findings indicate that digestive system conditions facilitate the formation of advanced glycation end product (AGE) precursors. Also, glyoxal and methylglyoxal levels were found to be low in chocolate samples containing dark chocolate. In contrast, they were found to be high in samples containing hazelnuts, almonds, pistache, and milk. Further studies should focus on α-DCs formation under digestive system conditions, including the colon, to determine the effects of gut microbiota.


Sujet(s)
Chocolat , Digestion , Glyoxal , Méthylglyoxal , Glyoxal/analyse , Méthylglyoxal/métabolisme , Méthylglyoxal/analyse , Chocolat/analyse , Chromatographie en phase liquide à haute performance , Produits terminaux de glycation avancée/métabolisme , Produits terminaux de glycation avancée/analyse , Biodisponibilité , Humains
14.
Indian J Public Health ; 68(1): 83-88, 2024 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-38847638

RÉSUMÉ

BACKGROUND: Obesity has reached an alarming rate affecting all categories of the population. A tremendous rise in obesity has been observed in children and adolescents. In India, the prevalence of adolescent obesity is more than 30% of the population. Advanced glycation end products (AGEs) are a diverse group of compounds formed by the amalgamation of glucose and a protein moiety. These glycated compounds are found in processed foods subjected to high-temperature cooking techniques contributing to the formation of dietary AGEs (dAGEs). The enormous consumption of dAGE attributes to the development of metabolic diseases. OBJECTIVES: The objective of this study was to develop and validate a food frequency questionnaire (FFQ) among obese adolescents aged 10-19 years to gauge their dAGE consumption. MATERIALS AND METHODS: This questionnaire was developed from previous literature (15 articles), validated using the content validity ratio (CVR) by Lawshe, and estimated for reliability using the test-retest method. A pilot study was done among 50 obese adolescents aged 10-19 years, who completed the questionnaire twice, with a gap of 15 days. RESULTS: A total of 54 items were validated (CVR ≥0.99) from the 60 food items. A reliability score >0.7 was observed, and a significant correlation (P ≥ 0.01) between the test and retest results was determined. CONCLUSION: Hence, this FFQ is reliable and can be used for future research studies to elicit dAGE consumption among obese adolescents.


Sujet(s)
Produits terminaux de glycation avancée , Humains , Adolescent , Enfant , Reproductibilité des résultats , Femelle , Mâle , Inde/épidémiologie , Enquêtes et questionnaires/normes , Jeune adulte , Obésité pédiatrique , Projets pilotes , Produits terminaux de glycation avancée alimentaires
15.
Arch Dermatol Res ; 316(7): 338, 2024 Jun 07.
Article de Anglais | MEDLINE | ID: mdl-38847916

RÉSUMÉ

Diabetic foot ulcer (DFU) is a predominant complication of diabetes mellitus with poor prognosis accompanied by high amputation and mortality rates. Dang-Gui-Si-Ni decoction (DSD), as a classic formula with a long history in China, has been found to improve DFU symptoms. However, mechanism of DSD for DFU therapy remains unclear with no systematic elaboration. In vivo, following establishment of DFU rat model, DSD intervention with low, medium and high doses was done, with Metformin (DM) as a positive control group. With wound healing detection, pathological changes by HE staining, inflammatory factor expression by ELISA and qRT-PCR, oxidative stress levels by ELISA, and AGEs/RAGE/TGF-ß/Smad2/3 expression by Western blot were performed. In vitro, intervention with LY2109761 (TGF-ß pathway inhibitor) based on DSD treatment in human dermal fibroblast-adult (HDF-a) cells was made. Cell viability by CCK8, migration ability by cell scratch, apoptosis by flow cytometry, and AGEs/RAGE/TGF-ß/Smad2/3 expression by Western blot were measured. DFU rats exhibited elevated AGEs/RAGE expression, whereas decreased TGF-ß1 and p-Smad3/Smad3 protein expression, accompanied by higher IL-1ß, IL-6, TNF-α levels, and oxidative stress. DSD intervention reversed above effects. Glucose induction caused lower cell viability, migration, TGF-ß1 and p-Smad3/Smad3 protein expression, with increased apoptosis and AGEs/RAGE expression in HDF-a cells. These effects were reversed after DSD intervention, and further LY2109761 intervention inhibited DSD effects in cells. DSD intervention may facilitate wound healing in DFU by regulating expression of AGEs/RAGE/TGF-ß/Smad2/3, providing scientific experimental evidence for DSD clinical application for DFU therapy.


Sujet(s)
Pied diabétique , Médicaments issus de plantes chinoises , Produits terminaux de glycation avancée , Protéine Smad2 , Protéine Smad-3 , Cicatrisation de plaie , Pied diabétique/traitement médicamenteux , Pied diabétique/métabolisme , Pied diabétique/anatomopathologie , Animaux , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Rats , Médicaments issus de plantes chinoises/pharmacologie , Protéine Smad2/métabolisme , Humains , Protéine Smad-3/métabolisme , Produits terminaux de glycation avancée/métabolisme , Mâle , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Facteur de croissance transformant bêta/métabolisme , Rat Sprague-Dawley , Stress oxydatif/effets des médicaments et des substances chimiques , Apoptose/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Diabète expérimental/métabolisme , Diabète expérimental/traitement médicamenteux , Fibroblastes/métabolisme , Fibroblastes/effets des médicaments et des substances chimiques , Mouvement cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques
16.
Mol Med ; 30(1): 76, 2024 Jun 05.
Article de Anglais | MEDLINE | ID: mdl-38840067

RÉSUMÉ

BACKGROUND: Advanced glycation end product-modified low-density lipoprotein (AGE-LDL) is related to inflammation and the development of atherosclerosis. Additionally, it has been demonstrated that receptor for advanced glycation end products (RAGE) has a role in the condition known as calcific aortic valve disease (CAVD). Here, we hypothesized that the AGE-LDL/RAGE axis could also be involved in the pathophysiological mechanism of CAVD. METHODS: Human aortic valve interstitial cells (HAVICs) were stimulated with AGE-LDL following pre-treatment with or without interleukin 37 (IL-37). Low-density lipoprotein receptor deletion (Ldlr-/-) hamsters were randomly allocated to chow diet (CD) group and high carbohydrate and high fat diet (HCHFD) group. RESULTS: AGE-LDL levels were significantly elevated in patients with CAVD and in a hamster model of aortic valve calcification. Our in vitro data further demonstrated that AGE-LDL augmented the expression of intercellular cell adhesion molecule-1 (ICAM-1), interleukin-6 (IL-6) and alkaline phosphatase (ALP) in a dose-dependent manner through NF-κB activation, which was attenuated by nuclear factor kappa-B (NF-κB) inhibitor Bay11-7082. The expression of RAGE was augmented in calcified aortic valves, and knockdown of RAGE in HAVICs attenuated the AGE-LDL-induced inflammatory and osteogenic responses as well as NF-κB activation. IL-37 suppressed inflammatory and osteogenic responses and NF-κB activation in HAVICs. The vivo experiment also demonstrate that supplementation with IL-37 inhibited valvular inflammatory response and thereby suppressed valvular osteogenic activities. CONCLUSIONS: AGE-LDL promoted inflammatory responses and osteogenic differentiation through RAGE/NF-κB pathway in vitro and aortic valve lesions in vivo. IL-37 suppressed the AGE-LDL-induced inflammatory and osteogenic responses in vitro and attenuated aortic valve lesions in a hamster model of CAVD.


Sujet(s)
Sténose aortique , Valve aortique , Calcinose , Produits terminaux de glycation avancée , Lipoprotéines LDL , Facteur de transcription NF-kappa B , Ostéogenèse , Récepteur spécifique des produits finaux de glycosylation avancée , Transduction du signal , Animaux , Valve aortique/métabolisme , Valve aortique/anatomopathologie , Produits terminaux de glycation avancée/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Humains , Calcinose/métabolisme , Calcinose/anatomopathologie , Calcinose/génétique , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Récepteur spécifique des produits finaux de glycosylation avancée/génétique , Sténose aortique/métabolisme , Sténose aortique/étiologie , Sténose aortique/anatomopathologie , Cricetinae , Ostéogenèse/effets des médicaments et des substances chimiques , Mâle , Lipoprotéines LDL/métabolisme , Modèles animaux de maladie humaine , Femelle , Adulte d'âge moyen , Protéines glyquées
17.
Nutrients ; 16(11)2024 Jun 01.
Article de Anglais | MEDLINE | ID: mdl-38892668

RÉSUMÉ

Dietary interventions are a key strategy to promote healthy ageing. Cooking skills training emerges as a promising approach to acquiring and maintaining healthy eating habits. The purpose was to evaluate the effectiveness of a culinary programme to improve healthy eating habits among overweight/obese adults (55-70 years old). A total of 62 volunteers were randomly (1:1) assigned to an culinary intervention group (CIG) or a nutritional intervention group (NIG). Dietary, cooking, and health-related outcomes, including body advanced glycation end product (AGE) levels, were evaluated at baseline and after four weeks. Mixed-effects linear models were used to assess the effects of the interventions within and between groups. Among the 56 participants who completed the trial, CIG participants achieved a significant improvement in Mediterranean diet adherence (1.2; 95%CI, 0.2 to 2.2) and a reduction in the use of culinary techniques associated with a higher AGE formation in foods (-2.8; 95%CI, -5.6 to -0.2), weight (-1.5; 95%CI, -2.5 to -0.5), body mass index (-0.5; 95%CI, -0.8 to -0.2), waist circumference (-1.4; 95%CI, -2.6 to -0.2), and hip circumference (-1.4; 95%CI, -2.4 to -0.4) compared with the NIG participants. Although a greater confidence in cooking in the CIG was found, attitudes and cooking habits did not improve. No significant differences in biochemical parameters or AGEs were found between groups. In conclusion, a culinary intervention could be successful in promoting healthy eating and cooking habits compared to a programme based on nutrition education alone. Nevertheless, further efforts are needed to strengthen attitudes and beliefs about home cooking, to address potential barriers and understand the impact of cooking interventions on biological parameters. Larger studies with longer follow-ups are needed to evaluate the relationship between cooking, diet, and health.


Sujet(s)
Cuisine (activité) , Études de faisabilité , Vieillissement en bonne santé , Humains , Adulte d'âge moyen , Cuisine (activité)/méthodes , Projets pilotes , Mâle , Sujet âgé , Femelle , Régime méditerranéen , Régime alimentaire sain/méthodes , Promotion de la santé/méthodes , Comportement alimentaire , Produits terminaux de glycation avancée/métabolisme , Obésité/prévention et contrôle , Surpoids/prévention et contrôle , Indice de masse corporelle
18.
Nutrients ; 16(11)2024 Jun 06.
Article de Anglais | MEDLINE | ID: mdl-38892723

RÉSUMÉ

As accumulated evidence suggests that individuals with post-traumatic stress disorder (PTSD) encounter earlier and more frequent occurrences of cardiovascular diseases, the aim of this study was to ascertain the differences in lifestyle and cardiovascular risk between PTSD and complex PTSD patients. We enrolled 137 male war veterans with PTSD (89 had complex PTSD). The diagnosis was established based on 11th revision of International Classification of Diseases (ICD-11), and cardiovascular risk was estimated by the measurement of advanced glycation end products. Adherence to Mediterranean diet (MD) was lower in the complex PTSD group (2.2% vs. 12.5%, p = 0.015). Accordingly, patients with complex PTSD had lower healthy lifestyle scores in comparison to PTSD counterparts (50.6 ± 9.7 vs. 59.6 ± 10.1, p < 0.001), and a positive association was noted between MD adherence and a healthy lifestyle (r = 0.183, p = 0.022). On the other hand, differences were not noted in terms of physical activity (p = 0.424), fat % (p = 0.571) or cardiovascular risk (p = 0.573). Although complex PTSD patients exhibit worse adherence to MD and lower healthy lifestyle scores, these differences do not seem to impact physical activity, body composition, or estimated cardiovascular risk. More research is needed to clarify if this lack of association accurately reflects the state of the PTSD population or results from insufficient statistical power.


Sujet(s)
Maladies cardiovasculaires , Régime méditerranéen , Exercice physique , Produits terminaux de glycation avancée , Facteurs de risque de maladie cardiaque , Troubles de stress post-traumatique , Anciens combattants , Humains , Régime méditerranéen/statistiques et données numériques , Troubles de stress post-traumatique/épidémiologie , Mâle , Anciens combattants/statistiques et données numériques , Anciens combattants/psychologie , Adulte d'âge moyen , Maladies cardiovasculaires/prévention et contrôle , Adulte , Mode de vie , Observance par le patient/statistiques et données numériques , Mode de vie sain
19.
Sensors (Basel) ; 24(11)2024 May 23.
Article de Anglais | MEDLINE | ID: mdl-38894145

RÉSUMÉ

Advanced glycation end-products (AGEs) are complex compounds closely associated with several chronic diseases, especially diabetes mellitus (DM). Current methods for detecting AGEs are not suitable for screening large populations, or for long-term monitoring. This paper introduces a portable autofluorescence detection system that measures the concentration of AGEs in the skin based on the fluorescence characteristics of AGEs in biological tissues. The system employs a 395 nm laser LED to excite the fluorescence of AGEs, and uses a photodetector to capture the fluorescence intensity. A model correlating fluorescence intensity with AGEs concentration facilitates the detection of AGEs levels. To account for the variation in optical properties of different individuals' skin, the system includes a 520 nm light source for calibration. The system features a compact design, measuring only 60 mm × 50 mm × 20 mm, and is equipped with a miniature STM32 module for control and a battery for extended operation, making it easy for subjects to wear. To validate the system's effectiveness, it was tested on 14 volunteers to examine the correlation between AGEs and glycated hemoglobin, revealing a correlation coefficient of 0.49. Additionally, long-term monitoring of AGEs' fluorescence and blood sugar levels showed a correlation trend exceeding 0.95, indicating that AGEs reflect changes in blood sugar levels to some extent. Further, by constructing a multivariate predictive model, the study also found that AGEs levels are correlated with age, BMI, gender, and a physical activity index, providing new insights for predicting AGEs content and blood sugar levels. This research supports the early diagnosis and treatment of chronic diseases such as diabetes, and offers a potentially useful tool for future clinical applications.


Sujet(s)
Produits terminaux de glycation avancée , Humains , Produits terminaux de glycation avancée/analyse , Femelle , Mâle , Adulte , Hémoglobine glyquée/analyse , Adulte d'âge moyen , Glycémie/analyse , Peau/composition chimique , Diabète/diagnostic , Diabète/sang , Fluorescence , Imagerie optique/méthodes , Imagerie optique/instrumentation , Spectrométrie de fluorescence/méthodes
20.
Nat Commun ; 15(1): 4985, 2024 Jun 11.
Article de Anglais | MEDLINE | ID: mdl-38862515

RÉSUMÉ

Hyperglycemia accelerates calcification of atherosclerotic plaques in diabetic patients, and the accumulation of advanced glycation end products (AGEs) is closely related to the atherosclerotic calcification. Here, we show that hyperglycemia-mediated AGEs markedly increase vascular smooth muscle cells (VSMCs) NF90/110 activation in male diabetic patients with atherosclerotic calcified samples. VSMC-specific NF90/110 knockout in male mice decreases obviously AGEs-induced atherosclerotic calcification, along with the inhibitions of VSMC phenotypic changes to osteoblast-like cells, apoptosis, and matrix vesicle release. Mechanistically, AGEs increase the activity of NF90, which then enhances ubiquitination and degradation of AGE receptor 1 (AGER1) by stabilizing the mRNA of E3 ubiquitin ligase FBXW7, thus causing the accumulation of more AGEs and atherosclerotic calcification. Collectively, our study demonstrates the effects of VSMC NF90 in mediating the metabolic imbalance of AGEs to accelerate diabetic atherosclerotic calcification. Therefore, inhibition of VSMC NF90 may be a potential therapeutic target for diabetic atherosclerotic calcification.


Sujet(s)
Athérosclérose , Protéine-7 contenant une boite F et des répétitions WD , Produits terminaux de glycation avancée , Souris knockout , Muscles lisses vasculaires , Myocytes du muscle lisse , Facteurs nucléaires-90 , Récepteur spécifique des produits finaux de glycosylation avancée , Animaux , Mâle , Souris , Produits terminaux de glycation avancée/métabolisme , Muscles lisses vasculaires/métabolisme , Muscles lisses vasculaires/anatomopathologie , Athérosclérose/métabolisme , Athérosclérose/génétique , Athérosclérose/anatomopathologie , Humains , Protéine-7 contenant une boite F et des répétitions WD/métabolisme , Protéine-7 contenant une boite F et des répétitions WD/génétique , Myocytes du muscle lisse/métabolisme , Myocytes du muscle lisse/anatomopathologie , Facteurs nucléaires-90/métabolisme , Facteurs nucléaires-90/génétique , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Récepteur spécifique des produits finaux de glycosylation avancée/génétique , Calcification vasculaire/métabolisme , Calcification vasculaire/anatomopathologie , Calcification vasculaire/génétique , Souris de lignée C57BL , Ubiquitination , Diabète expérimental/métabolisme , Diabète expérimental/complications , Diabète expérimental/génétique , Diabète expérimental/anatomopathologie , Hyperglycémie/métabolisme , Hyperglycémie/génétique , Plaque d'athérosclérose/métabolisme , Plaque d'athérosclérose/anatomopathologie , Plaque d'athérosclérose/génétique , Apoptose
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...